about
Targeting the mTOR kinase domain: the second generation of mTOR inhibitorsHypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancersThe two faces of miR-29Acute myeloid leukemia of a primary hepatic carcinoma patient after liver transplantation: a case report and literature reviewAllele-specific behavior of molecular networks: understanding small-molecule drug response in yeastExcessive autophagy contributes to neuron death in cerebral ischemiaClinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Insulin and TOR signal in parallel through FOXO and S6K to promote epithelial wound healing.Metagenomics and Single-Cell Omics Data Analysis for Human Microbiome Research.Validation of anti-aging drugs by treating age-related diseases.The intestinal TORC2 signaling pathway contributes to associative learning in Caenorhabditis elegans.Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis.From rapalogs to anti-aging formula.CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapyBiotechnological applications derived from microorganisms of the Atacama DesertObservations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration.Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation.AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.Mammalian target of rapamycin's distinct roles and effectiveness in promoting compensatory axonal sprouting in the injured CNS.Low concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice.Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.mTOR is out of control in polycystic kidney disease.From nature to the laboratory and into the clinicEvolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centreGerosuppression in confluent cells.Frontier of epilepsy research - mTOR signaling pathway.DAMPs, ageing, and cancer: The 'DAMP Hypothesis'.Perspectives of Targeting mTORC1-S6K1 in Cardiovascular AgingHistological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.Exploiting a precise design of universal synthetic modular regulatory elements to unlock the microbial natural products in Streptomyces.A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Koschei the immortal and anti-aging drugsmTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenibProstate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenograftsPoint mutations of protein kinases and individualised cancer therapy.Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?The effect of rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal ratsCancer in the transplant recipient.Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta
P2860
Q24622194-8FECA96F-FDE3-4E02-ACBC-3B252CC04BD8Q25255621-479FCC5C-BE54-4CD0-8173-D37D00DBCE27Q26996481-39A03599-A340-449D-8527-84FE47F2C39AQ28074030-09DD7936-5CCF-456D-B88F-9B13F61FE806Q28484846-768B851A-B7C4-48EC-95DE-3E565E70013EQ28578774-82F33A24-3564-490F-98F0-8469262A3C8EQ30412106-032E1AE8-3B91-47A7-BB7A-233E0CBA7CADQ30821111-6E7BC645-E324-4306-AF78-804906C7B3C4Q31140588-8568774D-E7DA-453D-BDA8-2A2EFEB0B0A0Q33588700-41167885-5BEA-48E9-830C-9DAF42B12C14Q33727929-5F021ECE-0A7F-4AEA-BEE5-297E29345EEFQ33757132-E6577898-AA47-4C38-987E-EFB91F1376BEQ33829205-8C2CBCD2-F74D-401C-9B21-99824DC02D5BQ33993634-706D0B90-831F-47DE-9F9D-FC8B0ACA3B8AQ34043563-E8302EED-A0D0-48DE-87FA-5FB03150E65BQ34086311-35523C49-119E-4EF1-B62E-189D9EAA40CAQ34288026-E92CEBD6-87B9-4557-91D1-A4AFC3FAE46AQ34334399-CCDA81F4-891A-4D4D-8AF8-D5ACF9672BC4Q34491707-1BA11F71-1AEF-4186-97BE-C526F92FB99DQ34498996-0EA6B409-3E62-49F5-8524-70FA84005A34Q34501488-5E177CA9-EC2C-4152-BD20-CE6CFED9BB08Q34600012-A801DD78-3345-42BE-BF02-10E01BE64231Q34657694-20449D15-B44F-42DB-84AD-31170CE81F19Q34959580-A2BFF220-E823-43BF-B908-BA1EB0FD363AQ34982499-DDB7D034-5D65-47A7-AA00-FFC2CE9E15B2Q35014198-BEB05E0E-403B-4009-B06F-6626AD96D8CCQ35558632-35081E58-37F9-4184-B752-D9BF99576CE0Q35693660-D2579F0E-262B-4AA2-B420-25A35C60EED2Q35935114-8568AC5A-F16E-40E7-A963-BEE2F5F2C6DDQ36120216-120F7D77-076A-453F-BC97-5FAE83B76E01Q36183858-CFFA20B0-5639-41C9-A54F-7DD9C9AD4E08Q36292001-2488FD8C-03CA-43F0-AC82-0DC689988B78Q36545458-B4078675-B8D6-4B97-90ED-81E173F8B387Q36576554-A17EBDB0-271E-44B6-8E8C-E43616669BBEQ36632245-514D3DF3-BFFE-4CE0-A597-12E1C360A196Q36655931-D6258425-03F3-44F6-80E3-8491001F8404Q36752124-76041E8D-5CF3-4DC8-92B0-C74D0B46B946Q36842368-47F89EF5-D777-4808-A4A3-96AF66B95BDFQ36938488-630D2D3A-7BF4-4BA9-BA75-D9AE07B0DC66Q37129967-6297E142-EB93-41BE-ABF5-124E5ACD0D63
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Rapamycin: an anti-cancer immunosuppressant?
@ast
Rapamycin: an anti-cancer immunosuppressant?
@en
Rapamycin: an anti-cancer immunosuppressant?
@nl
type
label
Rapamycin: an anti-cancer immunosuppressant?
@ast
Rapamycin: an anti-cancer immunosuppressant?
@en
Rapamycin: an anti-cancer immunosuppressant?
@nl
prefLabel
Rapamycin: an anti-cancer immunosuppressant?
@ast
Rapamycin: an anti-cancer immunosuppressant?
@en
Rapamycin: an anti-cancer immunosuppressant?
@nl
P1476
Rapamycin: an anti-cancer immunosuppressant?
@en
P2093
Brian K Law
P356
10.1016/J.CRITREVONC.2004.09.009
P577
2005-10-01T00:00:00Z